As healthcare continues its digital transformation, more and more health data from diverse populations are becoming available. Digital biomarkers are objective and quantifiable physiological and behavioural data that are collected and measured using digital devices, such as smartphones, wearables and implantables. What is the current acknowledge range for digital biomarkers and why are they useful? To what extent are they currently used to generate evidence and value? How are regulators and payers looking at digital biomarkers? How are they changing how future medicines might be developed and how can this lead to more personalised treatments?
Moderator: Jessica Smith, Co-Founder & CXO, SomX